Helixmith unveiled the outcome of its study on developing a treatment for painful neuropathy at the Keystone Symposia in the United States on Tuesday.
Kim Sun-young, founder and CEO of Helixmith, made the presentation in the form of “back translational research” – which unveiled the results phase 1, 2 and 3 of clinical trials and scientifically back them up with various phenomenon found in the process.
Responses from participants were favorable.
"Sounds like the clinical potential is massive, and I am surprised by how hepatocyte growth factor (HGF) to have platform-like characteristics on various diseases," Dr. Chas Bountra said. He is currently a professor and pro-vice-chancellor for innovation at the University of Oxford.
The Keystone Symposia has a tradition of valuing in-depth scientific analysis and discussion, which is different from the big general councils, business development, or a conference for networking purposes, according to Helixmith.
For example, a renowned pain expert from a university in Seattle, U.S., expressed much interest, saying if the information about gabapentin becomes an established theory, it will bring about an enormous change in the pharmaceutical market of diabetic peripheral neuropathy (DPN).
Since the U.S. government declared a war against opioid in April 2018, the industry and researchers stepped up efforts to develop pain treatments by mobilizing high technology, spurred in part by the U.S. government’s investment of more than 1 trillion won ($840 million) in their research and development alone.
"We are striving to become a company with the most innovative and competitive products in this area because only our Engensis (VM202) has entered the third clinical phase and become the first to achieve Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration," the company said in a news release.
<© Korea Biomedical Review, All rights reserved.>